Fidson Healthcare Plc delivered strong 2025 results, as revenue rose 41% to ₦119.06 billion.
Growth came mainly from ethical drugs, as sales increased 41.5% to ₦77.8 billion.
Fidson Revenue Growth Surge
Moreover, this segment remained the company’s largest revenue source, reflecting steady demand.
Profit And Cost Pressures
Profit before tax rose 94% to ₦14.96 billion from ₦7.7 billion in 2024.
As a result, the company showed resilient core operations despite a challenging environment.
However, rising costs weighed on overall performance during the year.
For instance, finance costs increased 30% to ₦7.13 billion due to higher borrowing rates.
In addition, the company issued commercial papers above 23%, increasing financing pressure.
Meanwhile, the company recorded a foreign exchange loss of ₦6.01 billion from imported inputs.
Read Also: Shareholder Exit Deepens Ellah Lakes’ ₦3.86Bn Loss
Similarly, tax expenses rose over 80% to ₦4.25 billion, adding to cost pressures.
Although finance income grew 140% to ₦144 million, it offered limited relief.
Balance Sheet And Outlook
At the same time, cost of sales climbed 42% to ₦69.84 billion.
Likewise, administrative expenses rose to ₦12.4 billion, alongside impairment provisions of ₦238 million.
On the balance sheet, interest-bearing loans fell 48.7% to ₦3.60 billion.
However, current loan obligations increased 15.9% to ₦10.41 billion.
Total equity increased 35% to ₦30.2 billion, supported by higher retained earnings.
Consequently, earnings per share rose from 192 kobo to 412 kobo.
Profit after tax increased 125% to ₦9.88 billion during the year.
Therefore, the company proposed a dividend of ₦1.50 per share, up from ₦1.00.
Ethical drugs remain central to operations, including antibiotics and chronic disease treatments.
However, Nigeria relies heavily on imports, exposing firms to foreign exchange risks.
Overall, the company achieved strong growth, but cost pressures remain a key concern.
